Study details
Enrolling now
Feasibility Trial of Sodium-Glucose CoTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
Ann & Robert H Lurie Children's Hospital of Chicago
NCT IDNCT06430684ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
40
Study length
about 1.8 years
Ages
12–25
Locations
1 site in IL
About this study
Researchers are testing if it's possible to enroll children with chronic kidney disease into a clinical trial of empagliflozin. It will also explore whether taking empagliflozin for three months improves blood, urine, and heart function tests.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Empagliflozin 10 MG
PhaseEARLY_Phase 1
DrugEmpagliflozin 10 MG
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine)
Endpoints
Secondary: Serum N-terminal pro-brain natruetic peptide (NT-proBNP), Systolic Blood Pressure, Urine Albumin to Creatinine Ratio (UACr)
Body systems
Renal